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The prevalence of gestational diabetes mellitus (GDM) is increasing worldwide and ranges between 5.2% and 40.4% across countries; this wide variability reflects multiple factors such as BMI, ethnicity, country income, and also the diagnostic criteria used \[[@CR1]\]. Based on the International Association of Diabetes in Pregnancy Study Group (IADPSG) criteria, the European prevalence of GDM is approximatively 13% \[[@CR2], [@CR3]\]. Medical nutritional therapy (diet and exercise) is the first step in the treatment of GDM \[[@CR4]\]. However, if the desired glycaemic goals are not achieved, pharmacological treatment will be required.

GDM is linked with a substantial lifetime risk of developing type 2 diabetes. A meta-analysis conducted on studies published over the last 50 years showed that women with a history of GDM have a higher risk of developing type 2 diabetes (RR 7.4) compared with women with normal glucose tolerance (NGT) in pregnancy \[[@CR5]\]. Women with previous GDM are more likely to develop the metabolic syndrome \[[@CR6]\] and cardiovascular disorders \[[@CR7]\] in later life. Several studies have shown that women with GDM have a higher risk of developing postpartum depression \[[@CR8], [@CR9]\]. There is also a growing body of literature associating a history of GDM with the development of tumours, particularly breast and endometrial tumours \[[@CR10]\].

Women with GDM should be screened for persistent diabetes or impaired fasting glucose and/or impaired glucose tolerance at 6--12 weeks postpartum using non-pregnancy criteria \[[@CR11]\]. However, there is no standardised approach to the long-term follow-up of women with a previous GDM diagnosis. The results of clinical trials evaluating comparable interventions are usually summarised in systematic reviews and meta-analyses that provide the basis for guidelines and treatment recommendations. However, there is little consistency in outcome selection and reporting in clinical trials involving this population. This inconsistency raises concern for possible outcome selection bias, makes significant research synthesis difficult and limits the ability to combine the findings of individual studies into summary estimates. One way to overcome this is to develop a core outcome set (COS).

A COS is the minimum set of outcomes that should be consistently measured and reported in all clinical trials (and other studies). However, this does not restrict researchers from adding additional outcomes. A minimum set of outcomes will provide greater uniformity of reporting in clinical trials and more data to impact meta-analyses. Also, a COS will reduce study heterogeneity and the risk of reporting bias by consistently measuring and reporting these outcomes.

The Core Outcome Measures in Effectiveness Trials (COMET) initiative aims to standardise outcome reporting in trials, facilitates participation of diverse experts undertaking research and minimises duplication of work \[[@CR12], [@CR13]\]. The Core Outcome Set STAndards for Reporting (COS-STAR) is a checklist designed to be applicable regardless of the consensus methods used to develop the COS and the various participant groups \[[@CR14]\]. The COS-STAR checklist provides guidance for minimal COS study reporting and its purpose is to promote the transparency and completeness of reporting in all COS studies. The CoRe Outcomes in Women's and Newborn health (CROWN) initiative encourages the development of COSs in women's and newborns' health.

The aim of this study was to develop a COS for trials and other studies evaluating the long-term follow-up at 1 year and beyond of women with previous GDM treated with insulin and/oral glucose-lowering agents. This study focuses only on women with GDM treated with insulin and oral glucose-lowering agents as this population has more severe glucose abnormalities and are more likely to progress to type 2 diabetes, obesity and the metabolic syndrome \[[@CR15], [@CR16]\].

Methods {#Sec2}
=======

This study is registered in the COMET database \[[@CR17]\]. Ethical approval for the study was obtained from the Galway University Hospitals Research Ethics Committee (reference CA 1905).

The three work packages of the study were: (1) a systematic review of literature that identified all the outcomes reported in clinical trials that involved the long-term follow-up of this population; (2) a Delphi survey in which all outcomes were scored and prioritised by key stakeholder groups to provide a preliminary list of final outcomes; and (3) a consensus meeting where the final list of outcomes was decided.

Systematic review {#FPar1}
-----------------

Using a broad-based search strategy, the following databases were searched for relevant studies between October 2017 and February 2018: Cochrane Central Register of Controlled Trials (CENTRAL), the Cumulative Index to Nursing and Allied Health Literature (CINAHL), PubMed, EMBASE and Web of Science. [ClinicalTrials.gov](http://clinicaltrials.gov) was also searched for relevant ongoing trials. The reference lists of all included studies were searched for additional studies not retrieved from the electronic database search. There was no time restriction on the date of publication of the studies. There was no language restriction applied to the search strategy. Only RCTs and RCT follow-up studies were included in the systematic review (an example of the search strategy is presented in the electronic supplementary material \[ESM\] Methods).

In step 1, all identified study titles were reviewed and ineligible studies excluded (F.P. Dunne and D. Bogdanet). In step 2, the remaining studies were appraised by two reviewers (F.P. Dunne and D. Bogdanet) who independently assessed the titles and abstracts of each study included at this stage. Full texts of studies meeting the inclusion criteria and studies for which there was uncertainty regarding inclusion at the title/abstract screening stage were retrieved and reviewed independently (F.P. Dunne and D. Bogdanet). The same two authors extracted the data independently, reviewed the data together, assessed consensus and ensured that all outcomes were identified. Following review by F.P. Dunne, D. Devane, D. Bogdanet, L. Biesty, A. M. Egan and P. M. O'Shea (the study advisory group \[SAG\]), extracted outcomes were grouped under the following domains: laboratory tests, clinical conditions, physiological variables, diet and exercise, psychological variables and other.

Delphi method {#FPar2}
-------------

We conducted a three-round eDelphi survey \[[@CR18]\]. This facilitated international participation. Questionnaires were completed online using SurveyMethods software ([www.surveymethods.com](http://www.surveymethods.com), SurveyMethods, Dallas, TX, USA, accessed 9 May 2018). Full details of our methods are given in Bogdanet et al (2019) \[[@CR19]\] and are described briefly below.

The stakeholder groups comprised: women with a previous diagnosis of GDM, endocrinologists, diabetes nurses, obstetricians, midwives, paediatricians, neonatologists, general practitioners, practice nurses, dietitians, physiotherapists, researchers with expertise in gestational diabetes, policy makers and others (which included clinicians with expertise in gestational diabetes from specialties other than endocrinology and obstetrics, epidemiologists, clinical biochemists and healthcare assistants).

Invitation emails were sent to societies and individual members of the IADPSG, Diabetes Ireland, Irish Endocrine Society (IES), IDF, International Federation of Gynecology and Obstetrics (FIGO), European Board and College of Obstetrics and Gynaecology (EBCOG), Irish Nutrition and Dietetic Institute (INDI), Association of Clinical Biochemists in Ireland (ACBI), Irish Institute of Obstetricians and Gynaecologists, Saolta Healthcare Group (Ireland), EASD, Diabetic Pregnancy Study Group (DPSG) of the EASD and the Royal College of Physicians Ireland (RCPI) (divisions of Endocrinology, Obstetrics and Endocrinology and Paediatrics). All participants were asked to forward the invitation to others whom they regarded as having the required expertise. Additionally, women with a history of GDM were contacted through their clinic by the authors and by additional study participants and, following consent, were forwarded the survey link or given a printed form of the survey. Women with GDM were from a number of clinics; the final group who participated in the consensus meeting were from the Galway clinic.

Study participants gave informed consent prior to the submission of any answers and the following information was also requested: name, email address, sex, stakeholder group and country of residence. Participants were given information about the study and about COSs. Participants were encouraged to complete the eDelphi questionnaire in each round. An email reminder was sent to anyone who did not respond after 7 and 14 days and also 3 days and 1 day before the end of the round.

In the first round of the survey, all the outcomes identified in the systematic review were presented to the participants grouped by domain. The study participants were asked to rate each outcome on a nine-point Likert scale (1--3 limited importance; 4--6 important but not critical, 7--9 critical). We provided all participants with plain English explanations of the outcomes included in the survey. Participants were invited to suggest additional relevant outcomes (no limit to the number of outcomes suggested) using free-text responses. If two or more study participants nominated an outcome, that outcome was included in round 2 of the survey.

All stakeholder groups were grouped into three broader groups, i.e. clinicians, women with a previous diagnosis of GDM and researchers/policy makers. Descriptive statistics were used to summarise the results from round 1. We sent individual results, the results of each stakeholder group and the results of the total group to each study participant. All outcomes including the additional outcomes suggested in round 1 (by two or more participants) were carried forward to round 2. All respondents to round 1 were invited to participate in round 2 and asked to re-rate the outcomes. All outcomes that scored 7--9 on the Likert scale in ≥70% of answers and 1--3 in \<15% of answers were carried forward to round 3. Each participant who completed round 2 was emailed their individual results and the results of each stakeholder group and the total group and was invited to participate in round 3 and re-score retained outcomes. Outcomes were classified as 'consensus in' (≥70% participants scoring as 7--9 and \<15% scoring as 1--3) or 'consensus out' (≥70% scoring as 1--3 and \<15% scoring as 7--9). The 'consensus in' and borderline outcomes were brought forward to the consensus meeting.

Consensus meeting {#FPar3}
-----------------

The consensus meeting involved representatives from each stakeholder group. The participants discussed each outcome brought forward from round 3. If necessary, the outcomes were grouped or renamed in order to facilitate dissemination and usefulness. At the end of the discussion, each participant voted 'outcome in' or 'outcome out' using the app Poll Everywhere (San Francisco, CA, USA, accessed 27 September 2018) on their electronic device, thus concealing their identity. Outcomes that scored over 70% 'outcome in', were included in the final COS.

Results {#Sec3}
=======

A total of 3344 titles and abstracts were identified. Following review of the title and/or abstracts, 62 full text papers were retrieved and assessed for eligibility. A further 37 papers were excluded following full text assessment, leaving 25 papers in the review (ESM Table [1](#MOESM1){ref-type="media"}). Following data extraction, 121 individual outcomes were identified. Following the SAG meeting, similar outcomes were combined, leaving a final 116 outcomes to be grouped and included in round 1 (ESM Fig. [1](#MOESM1){ref-type="media"}).

The first round of the Delphi survey was sent to 835 participants (societies and individual members). At the end of round 1, there were 288 respondents (34.5%) representing 33 countries and five continents (Table [1](#Tab1){ref-type="table"}). A total of 73% of the respondents were female. The distribution of answers throughout the stakeholder groups in each of the three rounds is presented in Table [1](#Tab1){ref-type="table"}. An additional ten outcomes were suggested by two or more study participants and were included in round 2 (ESM Table [2](#MOESM1){ref-type="media"}).Table 1Characteristics of participants in the Delphi online surveyVariableRound 1, % (*n* = 288)Round 2, % (*n* = 190)Round 3, % (*n* = 165)Sex (female)7373.772.1Experience/background  Diabetes nurse specialist5.56.35.5  Endocrinologist31.235.836.4  Obstetrician14.215.817.6  Paediatrician1.72.10.6  Neonatologist1.71.61.2  Midwife5.54.74.8  General practitioner3.83.13  Practice nurse0.30.50.6  Dietitian1.710.6  Physiotherapist100  Other11.811.612.1  Woman with previous diagnosis of GDM14.21010.3  Researcher with expertise in diabetes5.55.86.1  Policy maker1.41.60.6  Clinician78.982.683.3  Health service user14.21010.3  Researcher/policy maker6.97.46.7Participant's country of residence  Albania0.30.50.6  Argentina7.36.86.7  Australia3.14.23.6  Austria0.71.11.2  Belgium10.50.6  Canada11.61.8  Chile0.30.50.6  Croatia0.71.11.2  Czech Republic0.300  Denmark3.84.24.8  France1.32.12.4  Germany10.50.6  Greece0.71.10.6  Hungary0.300  India0.70.50.6  Ireland49.847.449  Israel0.700  Italy2.12.62.4  Jamaica0.30.50.6  Lithuania1.41.61.8  Malta0.30.50.6  The Netherlands0.71.10.6  New Zealand3.84.23  Nigeria0.30.50.6  Poland0.700  Portugal0.30.50  Romania0.71.11.2  Spain2.11.11.2  Sweden11.10.6  UAE0.70.50.6  UK7.46.44.8  USA4.25.86.8  Uruguay0.30.50UAE, United Arab Emirates

Round 2 participants were asked to rate 126 outcomes grouped as described in the Methods section. Round 2 was completed by 65.9% of the round 1 responders (190 participants). Similar to round 1, there was a female predominance among responders (73.7%). The distribution of answers amid stakeholder groups was similar to round 1 (Table [1](#Tab1){ref-type="table"}) (clinicians 82.6%, women with a history of GDM 10%, researchers/policy makers 7.4%). All outcomes that scored 7--9 on Likert scale in ≥70% and 1--3 in \<15% by study participants were brought forward to round 3 (*n* = 34). The percentage of participants who voted 1--3, 4--6 or 7--9 on each outcome at the end of round 2 is presented in Table [2](#Tab2){ref-type="table"}.Table 2Percentage of round 2 participants (*n* = 190) scoring each outcome as 1--3, 4--6 or 7--9 on the 9-point Likert scaleVariableScore 1--3, %Score 4--6, %Score 7--9, %Laboratory tests  75 g OGTT51184  Glucose level at 30 min during the 75 g OGTT532819  Glucose level at 1 h during the 75 g OGTT242353  Glucose level at 2 h during the 75 g OGTT71479  Glucose level at 3 h during the 75 g OGTT582814  Insulin level at 30 min during the OGTT533116  Insulin level at 2 h during the OGTT393724  Fasting glucose31582  Random glucose453619  HbA~1c~ level41383  Fasting HbA~1c~502030  Insulin level383428  Fasting insulin level283636  Insulin to glucose ratio284032  Insulinogenic index304228  Corrected insulin response374023  Insulin sensitivity254133  HOMA294229  HOMA-IR263935  HOMA-β284032  Triacylglycerol level243640  Fasting triacylglycerol level123355  Cholesterol level213742  Fasting cholesterol143749  HDL203644  Fasting HDL153847  LDL203347  Fasting LDL163648  Apo-lipoprotein B354619  Oxidised lipoproteins384616  ACR113752  Insulin growth factor453916  IGF-binding protein 3 level503713  Paraoxonase543313  Leptin404020  Adiponectin394219  Total circulating adiponectin434215  High sensitivity C-reactive protein354520  Fibrinogen473914  Alanine aminotransferase234631  Thyroid stimulating hormone164044  Free thyroxine283537  Total tissue plasminogen activator antigen493912  Cytokines474112  Genotype for Pro12Ala polymorphism573310  Plasma uric acid413821  γ-glutamyl aminotransferase304327  Vitamin D264232Clinical conditions  Type 2 diabetes0397  Insulin-treated type 2 diabetes3889  GDM in subsequent pregnancies0496  The metabolic syndrome21682  Impaired fasting glucose21484  Impaired glucose tolerance21484  Polycystic ovary syndrome42670  Cardiovascular disease21781Physiological variables  Weight1495  Height121276  BMI11386  Waist circumference21880  Hip circumference93457  Waist/hip ratio72865  Body fat83755  Lean mass74548  Post-pregnancy weight retention22474  BP11188  Resting BP21583  Systolic BP21286  Diastolic BP21286  Resting pulse63856Diet and exercise  Coffee intake225622  Tea intake255520  Alcohol intake53263  Protein intake124543  Carbohydrate intake82765  Fruit intake102862  Vegetable intake92962  Dairy intake83952  Fat intake103258  Fibre intake93853  Low glycaemic intake103555  Unsaturated fat intake133255  Saturated fat intake123157  Healthy fat intake142957  Low fat intake184042  Low carbohydrate high-fat diet173746  Nutrition composition133453  Food frequency132958  Portion size72766  Total caloric intake72667  Sweetened beverage intake92368  Physical activity2989  Walking/cycling to work72370  Time spent sitting62371  Time spent sleeping92665Psychological variables  Quality of life31879  Eating behaviour62470  Adverse emotional status42868  Mental health status42373  Anxiety43066  Depression42373  Activity to enhance mood82864  Postnatal depression51580Other  Smoking status4789  Quality adjusted life year63064  Healthcare costs113059  Lost productivity due to absence from work113950  Sickness resulting in absence from work113752  Satisfaction with research participation154144  Number of pregnancies since the index pregnancy61777  Health insurance253837  Income204040  Menopause status173548  Miscarriage after the index pregnancy112960  Breastfeeding in the index pregnancy51679  Breastfeeding at 1 year post delivery102862  Plans for future pregnancies102466  Employment status213544  Return to work after pregnancy184141  Current medications52174  Oral contraceptive use142363  Contraception method162757  Hormone replacement therapy163044  Hysterectomy253540  Oophorectomy263747  Genital malignancies203040

Round 3 was completed by 165 participants (86.8%). Similar to round 2, outcomes were brought forward when 70% or more participants scored the outcome as 7--9 and \<15% participants scoring as 1--3. In total, 30 outcomes went through the consensus meeting (ESM Table [3](#MOESM1){ref-type="media"}).

Consensus meeting {#FPar4}
-----------------

The consensus meeting involved 20 participants, a chairperson and an administrator. The stakeholder groups included four women with a history of gestational diabetes, one diabetes nurse specialist, two midwives, one policy maker, two paediatricians, one clinical biochemist, two researchers in the area of diabetes in pregnancy, one epidemiologist, two obstetricians and four endocrinologists. The participants represented ten countries and three continents. Before the discussion on each outcome, the participants were shown the previous voting results on that particular outcome by the total group and by each stakeholder group. Each outcome was discussed and there was agreement that some items should be grouped and/or rephrased. Therefore, '75 g oral glucose tolerance test', 'Blood glucose level at 2 h during the 75 g oral glucose tolerance test', 'Fasting glucose' and 'HbA~1c~ blood levels' were combined into 'Assessment of glycaemic status'. 'Type 2 diabetes' became 'Diagnosis of type 2 diabetes since the index pregnancy'. 'GDM in subsequent/future pregnancies' became 'Number of pregnancies with a diagnosis of GDM since the index pregnancy'. 'Impaired fasting glucose' and 'Impaired glucose tolerance' were combined into 'Diagnosis of prediabetes since the index pregnancy' and 'Breastfeeding after the index pregnancy' became 'Breastfeeding'.

Following discussion, the panel voted on each outcome to determine whether it should or should not be included in the final set. The final COS included nine outcomes and is presented in Table [3](#Tab3){ref-type="table"}, together with the percentage of participants that voted 'consensus in'.Table 3Final outcomes to be included in the COSOutcomeVotes for the outcome to be included in the final COS, %Assessment of glycaemic status100Diagnosis of T2DM since the index pregnancy90Number of pregnancies since the index pregnancy100Number of pregnancies with a diagnosis of GDM since the index pregnancy100Diagnosis of prediabetes since the index pregnancy100BMI100Post-pregnancy weight retention95Resting BP100Breastfeeding75T2DM, type 2 diabetes mellitus

Discussion {#Sec4}
==========

This study used robust methods to develop the first COS relevant to the follow-up of women with previous gestational diabetes treated with insulin and/or glucose-lowering agents. A Delphi consensus panel with 20 representatives from ten countries agreed on nine outcomes to be included in the final COS. It is advised that all studies in this area use this COS to facilitate comparison among studies and limit heterogeneity and reporting bias. The application of agreed methods in developing a COS and the participation of multiple stakeholder groups assure the wide applicability and dissemination of this COS.

The wide applicability of the study was one of the main reasons why the outcomes '75 g oral glucose tolerance test', 'Blood glucose level at 2 h during the 75 g oral glucose tolerance test', 'Fasting glucose' and 'HbA~1c~ blood levels' were combined into 'Assessment of glycaemic status'; in so doing, the COS permits researchers the opportunity to assess glycaemic status according to their own national guidelines and resources. In addition, this COS identifies 'what is to be collected' and not 'how it is to be collected', which will be the subject of future work. Similarly, 'Impaired fasting glucose' and 'Impaired glucose tolerance' were combined as 'Diagnosis of prediabetes since the index pregnancy' to give the COS a worldwide applicability in light of the variability in diagnostic tools and criteria. However, while we would recommend that collection and reporting of all outcomes in the COS is mandatory, researchers can choose to collect any additional outcomes required for their study, including specific indices of glycaemic control.

Of importance, the COS consensus meeting had representation from a variety of health professionals/specialties, both local and international, and included women with a previous diagnosis of GDM. This stakeholder composition permitted both the health professionals and women to bring their experience and perspectives to the issues under discussion. Each participant was able to have an understanding of what was important to the other person and what was feasible. Ultimately, this resulted in shared decision-making in a study that will impact future research of women with gestational diabetes.

There are some limitations to our study. Currently, there are no methods for sample size calculation for this type of study. To minimise the potential for selection bias, participants were invited through international organisations and personal professional email lists. Only participants who completed each survey round were recorded. From the totality of initial emails sent before round 1, we had a 35% response. This response rate, however, included participants from 33 countries and five continents. We had a 34% drop-off rate between round 1 and round 2, but, impressively, 87% of participants who completed round 2 also completed round 3. There was a low response rate among primary care physicians (3.5%).

Another potential limitation of this study is the large number of items to be scored in rounds 1 and 2 of the online Delphi survey, which may have impacted negatively on the survey response rate.

We had a large percentage of international participants, including individuals from high-income, upper- and lower-middle-income countries. However, low-income countries were under-represented, and this may limit the generalisability of this COS to certain parts of the world. The participants at the consensus meeting tried to overcome this by rephrasing or combining outcomes in order to increase the worldwide applicability of the COS.

The access to service users was limited by data protection laws, so participants were recruited through the clinical facilities. Despite this, 30% of respondents in round 1 were international service users. At the consensus meeting, 50% of service user participants were non-Irish. We sought international participation for the COS to have global relevance. The service user representatives made important suggestions on all the outcomes discussed at the consensus meeting. Anonymous voting (via the electronic app during this meeting) aimed to prevent participants feeling compelled to vote in a certain way. It has been advocated that the views of health service users should be given greater value in the development of a COS \[[@CR20]\] as outcomes reported for clinical studies might not reflect endpoints that are meaningful for them. Examples exist where health service users identified an outcome important to them as a group that might not have been considered by clinicians \[[@CR21]--[@CR23]\]. However, the responses from health service users and the responses from other stakeholder groups were generally concordant.

The strengths of the study include our use of robust methods in the COS development, including adherence to the COS-STAR statement, the thoroughness of the systematic review (six databases were searched for relevant studies), the high number of participants and the diversity of stakeholder groups participating at each stage of the COS.

Recent review papers have shown the degree of outcome reporting bias among studies, with the main outcome not being reported in up to 47% of the studies and inadequately reported in up to 76% of the studies reviewed \[[@CR24]--[@CR26]\]. Therefore, there is a cogent argument for creating and disseminating a COS to harmonise outcome reporting.

This is the first study to outline a COS for the long-term follow-up of women with previous GDM. We encourage all investigators undertaking research in this field to report, as a minimum, this COS to reduce reporting bias by allowing evidence synthesis across clinical studies. This will ultimately lead to improvements in the quality of research and delivery of evidence-based healthcare for women with GDM.
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